Angiogenesis and mast cell density in invasive pulmonary adenocarcinoma

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 4, 2012, Pages 537-541

  Ullah, Ehsan ^a   Nagi, Abdul H ^a   Lail, Raees ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

adenocarcinoma; angiogenesis; Lung cancer; mast cell density; patient survival

Indexed keywords

CD34 ANTIGEN; TOLONIUM CHLORIDE;

ADULT; ANGIOGENESIS; ARTICLE; CELL COUNT; CELL DENSITY; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE PULMONARY ADENOCARCINOMA; LUNG ADENOCARCINOMA; MALE; MAST CELL; MORPHOLOGY; PREDICTOR VARIABLE; SURVIVAL RATE; TUMOR BIOPSY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAST CELLS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 84875483105     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.106530     Document Type: Article

References (30)

1. Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol 2007;62:93-104.
2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
6. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
7. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
8. Badar F, Meerza F, Khokhar RA, Ali FA, Irfan N, Kamran S, et al. Characteristics of lung cancer patients-the Shaukat Khanum memorial experience. Asian Pac J Cancer Prev 2006;7:245-8.
9. Naseem N, Sadiq S, Nagi AH, Ashraf M. A pattern of carcinoma of lung as seen in a tertiary care hospital. Biomedica 2008;24:118-23.
10. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
11. Iqbal ZH. Presentation of lung cancer in south of Punjab. Biomedica 1997;13:6-10.
12. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: A meta-analysis. Lung Cancer 2001;31:139-48.
13. Park SK, Cho LY, Yang JJ, Park B, Chang SH, Lee KS, et al. Lung cancer risk and cigarette smoking, lung tuberculosis according to histologic type and gender in a population based case-control study. Lung Cancer 2010;68:20-6.
14. Rana F, Rana H, Gill J, Saeed K. Epidemiology of lung cancer in Pakistani patients-Our experience at Shaukat Khanum Memorial Cancer Hospital and Research Centre. Ann King Edward Med Uni 1998;4:47-9.
15. Molassiotis A, Lowe M, Blackhall F, Lorigan P. A qualitative exploration of a respiratory distress symptom cluster in lung cancer: Cough, breathlessness and fatigue. Lung Cancer 2011;71:94-102.
16. Cheville AL, Novotny PJ, Sloan JA, Basford JR, Wampfler JA, Garces YI, et al. Fatigue, dyspnea, and cough comprise a persistent symptom cluster up to five years after diagnosis with lung cancer. J Pain Symptom Manage 2011;42:202-12.
17. Daniels M, Wright G, Russell P, Williams R, Conron M, Wainer M. Comprehensive adenocarcinoma sub-typing predicts outcome after lung cancer resection. Heart Lung Circ 2011;20:250-84.
18. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
19. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I, et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 2002;8:3480-6.
20. Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY, et al. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 2011;73:366-74.
21. Liam CK, Pang YK, Leow CH, Poosparajah S, Menon A. Changes in the distribution of lung cancer cell types and patient demography in a developing multiracial Asian country: Experience of a university teaching hospital. Lung Cancer 2006;53:23-30.
22. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-58.
23. Eady RA, Cowen T, Marshall TF, Plummer V, Greaves MW. Mast cell population density, blood vessel density and histamine content in normal human skin. Br J Dermatol 1979;100:623-33.
24. Westphal E. Uber mastzellen. In: Ehrlich P, editor. Ferbenanlytische Untersuchungen Zur Histologie Und Klinik Des Blutes. Berlin: Hirschwald; 1891. p. 17.
25. Murdoch C, Muthana M, Coffelt SB Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-31.
26. Galinsky DS, Nechushtan H. Mast cells and cancer-no longer just basic science. Crit Rev Oncol Hematol 2008;68:115-30.
27. Nechushtan H. The complexity of the complicity of mast cells in cancer. Int J Biochem Cell Biol 2010;42:551-4.
28. Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, et al. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 2009;115:4156-66.
29. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 2009;374:379-86.
30. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.